Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.

Forest JC, Thériault S, Massé J, Bujold E, Giguère Y.

Clin Chem Lab Med. 2014 Aug;52(8):1169-78. doi: 10.1515/cclm-2013-0955.

PMID:
24535301
2.

[Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].

Gao J, Shen J, Jiang Y, Zhou X, Qi H, Liu X, Liu J, Yang J, Bian X.

Zhonghua Fu Chan Ke Za Zhi. 2014 Jan;49(1):22-5. Chinese.

PMID:
24694913
3.

Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort.

Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H.

BMC Pregnancy Childbirth. 2013 May 12;13:110. doi: 10.1186/1471-2393-13-110.

4.

Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A.

J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.

PMID:
22902831
5.

Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.

Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, Farina A, Zanello M, Lee KJ, Cha DH.

BMC Pregnancy Childbirth. 2014 Jan 20;14:35. doi: 10.1186/1471-2393-14-35.

6.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

7.

Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia.

Doherty A, Carvalho JC, Drewlo S, El-Khuffash A, Downey K, Dodds M, Kingdom J.

J Obstet Gynaecol Can. 2014 Aug;36(8):692-700.

PMID:
25222164
8.

Circulating angiogenic factors and the risk of preeclampsia.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.

N Engl J Med. 2004 Feb 12;350(7):672-83.

9.

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S.

N Engl J Med. 2016 Jan 7;374(1):13-22. doi: 10.1056/NEJMoa1414838.

10.

Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.

Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M.

Hypertension. 2011 Nov;58(5):859-66. doi: 10.1161/HYPERTENSIONAHA.111.174417.

11.
12.

Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.

Leaños-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, Molina-Pérez CJ, García-Paleta Y, Isordia-Salas I, Ramírez-Valenzuela KL.

J Rheumatol. 2015 Jul;42(7):1141-9. doi: 10.3899/jrheum.141571.

PMID:
25979720
13.

The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.

Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, McCance DR; Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group..

Diabetes Care. 2013 Nov;36(11):3671-7. doi: 10.2337/dc13-0944.

14.

Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.

Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM.

Obstet Gynecol. 2008 Jun;111(6):1403-9. doi: 10.1097/AOG.0b013e3181719b7a. Erratum in: Obstet Gynecol. 2008 Sep;112(3):710.

PMID:
18515525
15.

Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.

Vatten LJ, Åsvold BO, Eskild A.

Acta Obstet Gynecol Scand. 2012 Dec;91(12):1388-94. doi: 10.1111/j.1600-0412.2012.01516.x.

PMID:
22882089
16.
17.

Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.

Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N.

Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):225-30. doi: 10.1016/j.ejogrb.2013.08.040.

PMID:
24035323
18.

Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.

Andersen LB, Frederiksen-Møller B, Work Havelund K, Dechend R, Jørgensen JS, Jensen BL, Nielsen J, Lykkedegn S, Barington T, Christesen HT.

J Am Soc Hypertens. 2015 Feb;9(2):86-96. doi: 10.1016/j.jash.2014.11.008.

PMID:
25600419
19.

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group..

N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.

20.

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.

Gurnadi JI, Mose J, Handono B, Satari MH, Anwar AD, Fauziah PN, Yogi Pramatirta A, Rihibiha DD.

BMC Res Notes. 2015 Oct 4;8:534. doi: 10.1186/s13104-015-1506-0.

Items per page

Supplemental Content

Support Center